Reimagining the infrastructure of cancer care
We provide solutions across the industry to learn from and improve every person's experience with cancer. See how we're:
Clinicians, researchers, and regulators rely on FLATIRON HEALTH® technology and evidence to learn faster and power smarter care for every patient.
Achieve your oncology real-world evidence goals faster and more efficiently
Generate robust evidence and insights by partnering with Flatiron's expert team of clinicians, scientists, and health data analysts.
— Hear from our customers
Fit-for-purpose RWE solutions
Flatiron was chosen because it's fit for purpose. You have the right population and good sample size with data for the endpoint, which is overall response rate. A key learning is you need to choose a database with good quality.
— By the numbers
5 million+
5 million+ patient records de-identified and available for research
Unleash precision oncology with our customizable clinical decision support platform
Improve the patient experience, streamline operations, and increase revenue with instinctive workflows, up-to-date treatment guidelines, and actionable data.
— Hear from our customers
Expand insights at the point of care
Flatiron Assist is a decision support tool that helps us choose and find the right regimens for our patients, stay within NCCN guidelines, and the treatment plans are very robust and customizable.
— By the numbers
44% reduction
44% reduction in the number of unique regimens ordered across cancer centers using Flatiron Assist ™
Transforming cancer care takes all of us. Our vision is to build a world where technology and science close the gap between care and research.
Academic Medical Centers
Enable quality care by providing evidence-based treatment options to clinicians and run more efficient clinical research by surfacing trial-eligible patients directly in the EHR. Once enrolled, digitally transfer relevant trial data from the EHR to downstream systems.
HEOR & RWE Teams
Design and execute real-world studies including comparative effectiveness, modeling long-term survival, and analyzing treatment patterns to provide insights into a treatment's long-term effectiveness as well as support market access and reimbursement decisions.
how we partner
RWE Services Real-World Data Prospective Evidence Generation
Research & Early Development Teams
Quicken drug discovery and development by linking genomics data with clinical outcomes to help assess unmet need, generate hypotheses about biomarker resistance alterations and co-alterations, and inform decision-making.
how we partner
Regulatory Affairs Teams
Leverage Flatiron's extensive experience with regulatory-grade real-world data to develop regulatory strategies, prepare evidence packages for approval and post-market requirements, and lead regulatory engagement.
how we partner
Real-World Data RWE Services Value and Market Access
Community Oncology Practices
Deliver quality patient care with a cancer-specific EHR and surface evidence-based treatment options. For practices that support research, save time and gain accuracy through data-backed identification of eligible trial patients in the EHR and digitally transfer relevant study data seamlessly between the EHR and EDC.
how we partner
EHR Clinical Decision Support Value-Based Care
Market Access Teams
Demonstrate a cancer drug's value to payers and Health Technology Assessment (HTA) bodies to accelerate access to life-extending cancer treatments worldwide and ensure reimbursement and optimal pricing.
how we partner
Value and Market Access RWE Services Real-World Data
Pharmacovigilance & Epidemiology Teams
Monitor and assess the safety of cancer drugs, leveraging retrospective and prospective real-world studies to identify adverse events, detect safety signals, and provide insights into the long-term safety profile of cancer drugs beyond clinical trials.
how we partner
Portfolio Strategy and Commercial Teams
Generate fast insights to identify portfolio gaps and opportunities, refine your commercial strategy and provide real-time line of sight into the launch performance and uptake with tailored RWE solutions.
how we partner
Medical Affairs Teams
Leverage Flatiron's RWE solutions to generate insights for the scientific community, regulatory agencies, healthcare professionals, and the broader market to ensure that new drugs are developed, communicated, and utilized effectively and ethically.
how we partner
Explore the latest insights, research, and stories from Flatiron's global team.
The bladder cancer landscape is evolving rapidly. The emergence of immune checkpoint inhibitors (ICIs) has fundamentally reshaped treatment, especially for muscle-invasive (MIBC) and advanced disease cases, and antibody-drug conjugates (ADCs) have introduced a new level of precision by targeting proteins like Nectin-4 commonly found on bladder cancer cells. The combination of these novel modalities is now producing much better outcomes — even in the perioperative setting for MIBC patients where chemotherapy used to be the main option, as we recently learned at the 2026 ASCO Genitourinary Cancers Symposium in San Francisco.
In my work as a clinician, I've spent nearly two decades watching the same pattern repeat itself: the treatments that earn approval through randomised controlled trials, our gold standard for evidence, are often tested on populations that don't look like the patients sitting in my clinic. The gap between what clinical trials demonstrate and what I observe in clinical practice isn't merely theoretical—it's reflected in patients sitting in our clinics—and this is precisely where real-world evidence becomes not just valuable but essential.
STUDY: Cancer patients experience longer survival in community oncology settings, affirming the high-quality care delivered across community practices
If there’s a question I hear most often from researchers it’s: How can we trust real-world data extracted by AI?